|[October 09, 2013]
NeuroVive Pharmaceutical: Catharina Johansson Appointed New CFO, Effective 1 December
STOCKHOLM --(Business Wire)--
NeuroVive Pharmaceutical AB (publ)(STO:NVP), a leading mitochondrial
medicine company, has appointed Catharina Johansson as the company's new
CFO. She will take up her position on 1 December. This appointment
concludes the recruitment process initiated earlier this year when the
company's previous CFO, Christian Svensson, announced his decision to
step down, to focus on his own consulting practice.
Catharina Johansson was formerly Interim CFO of medical technology
company Cellavision, listed on NASDAQ OMX Stockholm, as well as Head of
Accounting at Bong and Alfa Laval Europe. She holds an M.Sc. in Business
and Economics and is based in Lund, Sweden where NeuroVive's
headquarters are located.
Mikael Brönnegård, CEO of NeuroVive Pharmaceutical AB, said: "Catharina
Johansson's experience from a listed medical technology growth company
with international operations means she's well prepared for the role as
CFO of NeuroVive. I'm certain that her experience and drive will be a
great asset to NeuroVive when we develop our position as a leader with
many international collaborations and revenue sources."
Catharina Johansson, the new CFO of NeuroVive Pharmaceutical AB, sid:
"NeuroVive is right in a really interesting development phase, and I
look forward to using my experience of similar positions to help move
the company forward. I prefer dynamic companies that present constant
challenges, so I expect to fit well into NeuroVive's development-driven
NeuroVive's former CFO Christian Svensson will continue to serve the
company on a consultancy basis until Catharina takes up her new
position, and during a transitional phase. Accordingly, the transition
is expected to be smooth, with no effect on day-to-day business.
NeuroVive Pharmaceutical AB, a leading mitochondrial medicine company,
is developing a portfolio of products to treat acute cardiovascular and
neurological conditions through mitochondrial protection. These medical
conditions are characterized by a pressing medicinal need and have no
approved pharmaceutical treatment options at present. NeuroVive's
products CicloMulsion® (heart attack) and NeuroSTAT® (traumatic brain
injury) are currently being evaluated in phase III and phase II studies,
respectively. NeuroVive's research programs also include products for
the treatment of anti-viral indications (Hepatitis B/C), brain cell
injury in stroke patients, and drug candidates for cellular protection
and treating mitochondria-related energy regulation diseases.
NeuroVive's shares are listed on NASDAQ OMX, Stockholm, Sweden.
Please also use the above contact if you wish to arrange an interview
with NeuroVive's CEO, Mikael Brönnegård.
NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden, tel: +46 (0)46 275 6220
(switchboard), Fax: +46 (0)46 888 8348, email@example.com,
NeuroVive Pharmaceutical AB (publ) is obligated to publish the
information contained in this press release in accordance with the
Swedish Securities Market Act. This information was provided to the
media for publication at 08:00 a.m. CEST on October 9, 2013.
This information was brought to you by Cision http://news.cision.com
[ Back To Technology News's Homepage ]